Dianthus Sees Best-In-Class Potential For Claseprubart In Crowded gMG Market

Phase III Initiation, Data In Other Indications Due In 2026

 
• By Mandy Jackson
  
Dianthus will test 300mg claseprubart dosed every two and four weeks in its Phase III myasthenia gravis trial (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D